Journal
Journal of Allergy and Clinical Immunology
Publication Date
7-1-2021
Volume
148
Issue
1
First Page
164
Last Page
172.e9
Document Type
Open Access Publication
DOI
10.1016/j.jaci.2020.10.015
Rights and Permissions
Zuraw B, Lumry WR, Johnston DT, Aygören-Pürsün E, Banerji A, Bernstein JA, Christiansen SC, Jacobs JS, Sitz KV, Gower RG, Gagnon R, Wedner HJ, Kinaciyan T, Hakl R, Hanzlíková J, Anderson JT, McNeil DL, Fritz SB, Yang WH, Tachdjian R, Busse PJ, Craig TJ, Li HH, Farkas H, Best JM, Clemons D, Cornpropst M, Dobo SM, Iocca HA, Kargl D, Nagy E, Murray SC, Collis P, Sheridan WP, Maurer M, Riedl MA. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial. J Allergy Clin Immunol. 2021 Jul;148(1):164-172.e9. doi: 10.1016/j.jaci.2020.10.015. Copyright 2020 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY-NCND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Recommended Citation
Zuraw, Bruce; Wedner, H James; and et al., "Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial." Journal of Allergy and Clinical Immunology. 148, 1. 164 - 172.e9. (2021).
https://digitalcommons.wustl.edu/oa_4/1760
Department
ICTS (Institute of Clinical and Translational Sciences)
